港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

483.155

-13.603-2.74%

漲家數：7

跌家數：23

平家數：3

市盈率：- -

高：496.758

開：496.758

低：480.328

收：496.758

成交量：1.15億

成交額：26.12億

市值：3,069.30億

流通市值：2,732.98億

資料載入中...

港股異動 | 禮邦醫藥-B(09637)升逾6% 納入港股通及恒生綜合指數落地美信羅銷售按年增約105% 商業化兑現

大瓜！券商醫藥研究員轉行看電子去了

上半年創新藥冰火兩重天：百濟神州一款藥賣了超160億元，六成藥企還在求生

每日经济新闻

歸創通橋(02190.HK)9月7日耗資約113.9萬港元回購5.35萬股

榮昌生物：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告

证券日报网

康寧傑瑞製藥-B(09966)9月7日斥資98.92萬港元回購11.5萬股

康寧傑瑞製藥-B(09966.HK)9月7日斥資98.92萬港元回購11.5萬股

曾被估價1.54億元,如今2400萬元掛牌濟南平嘉大藥房60%股權再尋買家

艾迪藥業：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告

证券日报网

轉型陣痛的昂利康：傳統業務增長失速，豪賭創新藥前景未明

永泰生物－Ｂ(06978)股價顯著下跌10.127%，現價港幣$0.355

阿斯达克财经

新股前瞻|上市後首次半年報盈利，澤璟製藥(688266.SH)叩關港交所難言順利？

港股異動 | 歌禮制藥-B(01672.HK)午後升逾6% 公司正式進入港股通名單 ASC30近期完成首例入組

麥科田（2041.HK）登陸港交所，平台型醫療器械龍頭起航

同源康醫藥－Ｂ(02410)股價大幅下跌26.833%，現價港幣$4.54

阿斯达克财经

山東省寧陽縣市場監管局開展醫療器械專項現場檢查

中国质量新闻网

歌禮制藥納入港股通今日正式生效

歌禮制藥-B獲納入滬深港通下港股通名單

歌禮制藥-B(01672.HK)獲納入滬港通及深港通計劃項下的港股通名單

又一家醫療器械企業登陸港股，麥科田(02041)「含金量」幾何？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1574/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.606253","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":160.422718,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665334349","title":"港股異動 | 禮邦醫藥-B(09637)升逾6% 納入港股通及恒生綜合指數落地 美信羅銷售按年增約105% 商業化兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2665334349","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665334349?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 10:16","pubTimestamp":1788833785,"startTime":"0","endTime":"0","summary":"深交所9月7日公告亦确认09637调入港股通标的证券名单。礼邦医药于8月26日披露上市后首份中期业绩，2026年上半年收入人民币1.042亿元，同比增长761.2%，主要来自美信罗销售及AP306许可收入，期内亏损人民币1.626亿元，同比收窄22.5%。其中，商业化产品美信罗实现销售收入人民币2480万元，同比增长约105%，覆盖医院超300家，毛利率由2025年上半年的43.4%升至47.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","KCAI","09637","BK1515","09939","BK4585","159938","BK1191","VXUS","BK1574","FLHK","HSCI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665312996","title":"大瓜！券商醫藥研究員轉行看電子去了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665312996","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665312996?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 21:05","pubTimestamp":1788786300,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！（来源：花尔街之狼）券商医药研究员转行看电子去了本科硕士都学的医学，怎么转行看电子了？","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-07/doc-iniqzhfu5386610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KCE","159938","BK1515","BK1161","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311078","title":"上半年創新藥冰火兩重天：百濟神州一款藥賣了超160億元，六成藥企還在求生","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311078","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665311078?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 20:39","pubTimestamp":1788784781,"startTime":"0","endTime":"0","summary":"2026年上半年财报季收官，中国创新药产业交出了一份分水岭式的答卷。行业正在告别“烧钱讲故事”的阶段，走向“赚钱才是硬道理”的价值兑现期。这种转变并非行业普遍现象，而是由商业化放量、出海授权爆发、资金来源多元化三重力量共同推动的分化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866904351.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866904351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","LU0307460666.USD","LU1303224171.USD","LU1719994722.HKD","LU0228659784.USD","688235","MEDX","LU0588546209.SGD","BK4585","BK1500","LU1969619763.USD","LNGR","LU1251922891.USD","BK4526","LU0828237510.HKD","LU2328871848.SGD","BK1161","BK1583","BK4588","06160","IBBQ","LU1770034418.SGD","KURE","06978","BK1588","159992","BK4139","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665831152","title":"歸創通橋(02190.HK)9月7日耗資約113.9萬港元回購5.35萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665831152","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665831152?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 20:13","pubTimestamp":1788783192,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02190","BK1583","BK1100","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665731933","title":"榮昌生物：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665731933","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665731933?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，荣昌生物发布公告称，公司计划于2026年9月16日15：00-17：00参加2026年半年度科创板创新药行业集体业绩说明会，就投资者关心的问题进行交流。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxs9619866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1969619763.USD","LU2328871848.SGD","BK1574","159992","688331","KSTR","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","MEDX","BK1161","LNGR","IBBQ","BK1583","LU2488822045.USD","06978","BK0239","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665441315","title":"康寧傑瑞製藥-B(09966)9月7日斥資98.92萬港元回購11.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665441315","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665441315?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:17","pubTimestamp":1788776264,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年9月7日斥资98.92万港元回购11.5万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康宁杰瑞制药-B(09966)9月7日斥资98.92万港元回购11.5万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665315426","title":"康寧傑瑞製藥-B(09966.HK)9月7日斥資98.92萬港元回購11.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665315426","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665315426?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:17","pubTimestamp":1788776264,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319588","title":"曾被估價1.54億元,如今2400萬元掛牌 濟南平嘉大藥房60%股權再尋買家","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319588","media":"经济导报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319588?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:08","pubTimestamp":1788775680,"startTime":"0","endTime":"0","summary":"目前,济南平嘉股东分别为天士力医药和董红兵,持股比例分别为60%和40%。此次挂牌转让的,正是天士力医药所持有的60%股权。此次挂牌之所以引发关注,一个重要原因在于济南平嘉60%股权此前曾以较高价格进入市场视野。当时的评估结果显示,以2023年3月31日为评估基准日,济南平嘉100%股权评估值为26071.26万元,评估增值率达到1099.54%。如今,两年多时间过去,济南平嘉60%股权再次被摆上产权交易市场,挂牌底价已经变为2400万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-07/doc-iniqyzxs9592354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301017","BK1515","BK1574","BK0209","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319730","title":"艾迪藥業：關於參加科創板2026年半年度創新藥行業集體業績説明會的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319730","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319730?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:01","pubTimestamp":1788775260,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，艾迪药业发布公告称，公司计划于2026年9月16日15：00-17：00参与由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-07/doc-iniqyzxw5472550.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-07/doc-iniqyzxw5472550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","KSTR","MEDX","BK1574","LNGR","BK0262","IBBQ","688488","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665904373","title":"轉型陣痛的昂利康：傳統業務增長失速，豪賭創新藥前景未明","url":"https://stock-news.laohu8.com/highlight/detail?id=2665904373","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665904373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:08","pubTimestamp":1788768480,"startTime":"0","endTime":"0","summary":"证券之星注意到，2026年上半年，昂利康营收、净利双双下滑逾10%，传统业务中原料药收入持续缩水，特色中间体规模更是“腰斩”，成为主要拖累。传统业务增长失速、创新业务远水难解，昂利康能否在多重压力中突围，仍有待时间检验。昂利康提示风险称，肿瘤创新药产品各阶段的成功率相对于其他创新药低，风险较高，不确定性较大。昂利康如何在传统业务与创新药漫长培育期之间找到平衡，才是市场关注的焦点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-09-07/doc-iniqyvry5536300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","LNGR","002940","159992","BK1574","BK0239","BK1161","MEDX","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665492390","title":"永泰生物－Ｂ(06978)股價顯著下跌10.127%，現價港幣$0.355","url":"https://stock-news.laohu8.com/highlight/detail?id=2665492390","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665492390?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 15:59","pubTimestamp":1788767940,"startTime":"0","endTime":"0","summary":"[下跌股]永泰生物－Ｂ(06978) 股价在下午03:58比前收市价显著下跌10.127%，现股价为港币$0.355。至目前为止，今日最高价为$0.4，而最低价为$0.355。总成交量为26.5万股，总成交金额为港币$10.454万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609072672/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609072672/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665002392","title":"新股前瞻|上市後首次半年報盈利，澤璟製藥(688266.SH)叩關港交所難言順利？","url":"https://stock-news.laohu8.com/highlight/detail?id=2665002392","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665002392?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 15:13","pubTimestamp":1788765191,"startTime":"0","endTime":"0","summary":"近日，据港交所披露，苏州泽璟生物制药股份有限公司已向港交所主板递交上市申请，中金公司担任独家保荐人。截至目前，公司已拥有四款上市产品，随着纳入医保后市场打开，快速放量有望提升公司后续的盈利表现。截至2026年9月4日收市，泽璟制药的A股股价报收117.99元，总市值约为人民币312亿元。上半年该药销售收入960万元，销量1100盒，平均售价每盒9153.8元，毛利率为66.2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","688266","HEXmain","IPOS","01477","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665394527","title":"港股異動 | 歌禮制藥-B(01672.HK)午後升逾6% 公司正式進入港股通名單  ASC30近期完成首例入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2665394527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665394527?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 14:15","pubTimestamp":1788761745,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1515","BK1191","BK1574","01477","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665945893","title":"麥科田（2041.HK）登陸港交所，平台型醫療器械龍頭起航","url":"https://stock-news.laohu8.com/highlight/detail?id=2665945893","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665945893?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 14:10","pubTimestamp":1788761405,"startTime":"0","endTime":"0","summary":"麦科田通过多赛道布局、全球化运营、持续并购整合，构建一个抗周期、可持续的医疗器械平台。","market":"fut","thumbnail":"https://img2.gelonghui.com/52490-957b9937-e172-429c-8c01-0917b7b8c624.jpg?guru_height=2666&guru_width=4000&guru_size=1163899","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/52490-957b9937-e172-429c-8c01-0917b7b8c624.jpg?guru_height=2666&guru_width=4000&guru_size=1163899"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6537932","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LGHT","GDOC","PTH","MEDX","RSPH","BK1583","HART","BK1100","159883","09996","LNGR","MDEV","02041","BK1574","IEIH","AGNG","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665394677","title":"同源康醫藥－Ｂ(02410)股價大幅下跌26.833%，現價港幣$4.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2665394677","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665394677?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 14:04","pubTimestamp":1788761040,"startTime":"0","endTime":"0","summary":"[下跌股]同源康医药－Ｂ(02410) 股价在下午02:04比前收市价大幅下跌26.833%，现股价为港币$4.54。至目前为止，今日最高价为$5.905，而最低价为$4.54。总成交量为538.3万股，总成交金额为港币$2.673千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609072429/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609072429/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","159938","BK1574","BK1161","BK1515","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665399937","title":"山東省寧陽縣市場監管局開展醫療器械專項現場檢查","url":"https://stock-news.laohu8.com/highlight/detail?id=2665399937","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665399937?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 12:37","pubTimestamp":1788755820,"startTime":"0","endTime":"0","summary":"中国质量新闻网讯 9月7日，山东省宁阳县市场监管局执法人员深入辖区零售药店，开展医疗器械专项现场检查。执法人员重点查看血压计等二类医疗器械，仔细核对产品注册资料、进货票据，查验产品有效期、包装标识，排查有无过期失效、来路不明产品等风险隐患。检查过程坚持监管和指导同步开展，现场向药店从业人员讲解医疗器械经营相关规定，指出经营中的不足，督促经营者落实主体责任，规范进货查验和日常自查工作。下一步，该局将持续加大医疗器械监管频次，紧盯零售药店经营风险，切实保障群众用械安全。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-07/doc-iniqykzy9680694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","MEDX","RSPH","GDOC","PTH","LNGR","BK1583","BK1100","09996","159883","HART","LGHT","AGNG","MDEV","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665399941","title":"歌禮制藥納入港股通 今日正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2665399941","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665399941?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 12:25","pubTimestamp":1788755100,"startTime":"0","endTime":"0","summary":"歌礼制药（01672）发布公告，公司于2026年9月7日起，获纳入沪港通及深港通计划下的港股通名单。此次纳入将使符合相关资格的国内投资者能够通过港股通渠道交易公司股票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866532228.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866532228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1574","01477","BK1191","01672","FLHK","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164090375","title":"歌禮制藥-B獲納入滬深港通下港股通名單","url":"https://stock-news.laohu8.com/highlight/detail?id=1164090375","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164090375?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 12:18","pubTimestamp":1788754680,"startTime":"0","endTime":"0","summary":"歌礼制药-B（Ascletis-B）宣布，公司已成功入选港股通名单，该名单适用于上海-香港股票市场交易互联互通机制以及深圳-香港股票市场交易互联互通机制。这一里程碑式的进展，标志着公司股票正式进入沪深港通体系，为两地投资者提供了更为便捷的投资通道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665352399","title":"歌禮制藥-B(01672.HK)獲納入滬港通及深港通計劃項下的港股通名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2665352399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665352399?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 12:16","pubTimestamp":1788754601,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01477","BK1161","01672","BK1574","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665399350","title":"又一家醫療器械企業登陸港股，麥科田(02041)「含金量」幾何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2665399350","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665399350?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 12:07","pubTimestamp":1788754034,"startTime":"0","endTime":"0","summary":"随着多家医疗器械企业中报密集披露，医疗器械板块整体修复态势明确，业绩端已出现向上拐点。9月7日，麦科田正式于港交所挂牌上市，这意味着港股医疗器械板块再添一家平台型龙头。据多家权威机构测算，2026年全球医疗器械市场规模预计在6000亿至8000亿美元之间，并有望于2035年突破万亿美元大关。整体来看，麦科田此次登陆港股，业绩方面盈利拐点已经确认，商业化路径成熟，平台型的全面产品组合和全","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK1574","MEDX","RSPH","MDEV","VXUS","GDOC","IEIH","LGHT","PTH","BK4585","LNGR","BK1583","159883","02041","HART","BK1100","KCAI","AGNG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":7,"totalSize":344,"code":"91000000","status":"200"}]}}